Blanchard Karen, Colbert James A, Kopans Daniel B, Moore Richard, Halpern Elkan F, Hughes Kevin S, Smith Barbara L, Tanabe Kenneth K, Michaelson James S
Department of Surgery, Massachusetts General Hospital, Yawkey 7939, 55 Fruit St, Boston, MA 02114, USA.
Radiology. 2006 Aug;240(2):335-42. doi: 10.1148/radiol.2402050107.
To retrospectively determine the long-term risk of false-positive mammographic assessments and to evaluate the effect of screening regularity on the risk of false-positive events.
Institutional review board approval was obtained, and informed consent was waived. Retrospective analysis was performed for the occurrence of false-positive assessments among 83,511 women who underwent 314,185 mammographic examinations from January 1, 1985, to February 19, 2002. Data were collected from a database that had been assembled prospectively. Two categories of false-positive events were examined: biopsies that did not reveal cancer and false-positive mammographic assessments. Rates of false-positive events were compared by using a chi2 analysis, and 95% confidence limits were calculated. Because comparisons of multiple pairs were considered, all P values that demonstrated statistical significance exceeded the requirement of the Bonferroni correction.
While the overall rates of biopsies that did not reveal cancer and of false-positive mammographic assessments were similar to those found in other studies, most of the burden of false-positive events was borne by women who underwent intermittent screening. Long-term rates of false-positive events were lower among women who underwent regular screening than among those who underwent intermittent screening. In the 5-year group, 2.9% of women who underwent five mammographic examinations over the next 5 years had biopsy results that did not reveal cancer, whereas 4.6% of women who underwent three mammographic examinations over the next 5 years had biopsy results that did not reveal cancer. For women who underwent regular screening, the risk of undergoing biopsies that did not reveal cancer declined over time to 0.25% per year after several years of screening, a value that is lower than the risk of these events among women who did not undergo screening. The rate of false-positive mammographic assessments was also lower for women who underwent regular screening than for those who underwent intermittent screening.
Prompt annual attendance for mammographic screening reduces the occurrence of false-positive mammographic results.
回顾性确定乳腺钼靶检查假阳性评估的长期风险,并评估筛查规律性对假阳性事件风险的影响。
获得机构审查委员会批准,且无需知情同意。对1985年1月1日至2002年2月19日期间接受314,185次乳腺钼靶检查的83,511名女性中假阳性评估的发生情况进行回顾性分析。数据从一个前瞻性收集的数据库中获取。检查了两类假阳性事件:未发现癌症的活检以及乳腺钼靶检查假阳性评估。使用卡方分析比较假阳性事件的发生率,并计算95%置信区间。由于考虑了多组比较,所有具有统计学意义的P值均超过了Bonferroni校正的要求。
虽然未发现癌症的活检和乳腺钼靶检查假阳性评估的总体发生率与其他研究中的相似,但大部分假阳性事件负担由接受间歇性筛查的女性承担。接受定期筛查的女性假阳性事件的长期发生率低于接受间歇性筛查的女性。在5年组中,在接下来5年接受5次乳腺钼靶检查的女性中有2.9%的活检结果未发现癌症,而在接下来5年接受3次乳腺钼靶检查的女性中有4.6%的活检结果未发现癌症。对于接受定期筛查的女性,经过数年筛查后,未发现癌症的活检风险逐年下降至每年0.25%,这一数值低于未接受筛查女性中这些事件的风险。接受定期筛查的女性乳腺钼靶检查假阳性评估率也低于接受间歇性筛查的女性。
每年及时进行乳腺钼靶筛查可减少乳腺钼靶检查假阳性结果的发生。